Crossmark

A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy

Crossref DOI link: https://doi.org/10.1038/s41375-020-0892-z

Published Online: 2020-06-19

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wass, Maxi

Göllner, Stefanie

Besenbeck, Birgit

Schlenk, Richard F.

Mundmann, Petra

Göthert, Joachim R.

Noppeney, Richard

Schliemann, Christoph

Mikesch, Jan-Henrik

Lenz, Georg

Dugas, Martin https://orcid.org/0000-0001-9740-0788
Wermke, Martin

Röllig, Christoph https://orcid.org/0000-0002-3791-0548
Bornhäuser, Martin

Serve, Hubert

Platzbecker, Uwe

Foerster, Kathrin I.

Burhenne, Jürgen

Haefeli, Walter E.

Müller, Lutz P.

Binder, Mascha

Pabst, Caroline https://orcid.org/0000-0001-9716-5909
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
,
License Information

Text and Data Mining valid from 2020-06-19

Version of Record valid from 2020-06-19
More Information

Article History

Received: 29 August 2019

Revised: 16 April 2020

Accepted: 26 May 2020

First Online: 19 June 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below